Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.55 EPS, down 100% or $0.55 from last year’s $n/a per share.

At the moment 3 analysts are watching Calithera Biosciences, Inc. (NASDAQ:CALA), 2 rate it “Buy”, 1 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 3 analysts have a mean target of 0.00 million.

In terms of earnings per share, 1 analyst has a -0.61 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.62 EPS mean target and for the quarter ending Jun-16 there are 3 estimates of -2.83 EPS.

The biggest institutional shareholders in Calithera Biosciences, Inc. include Adage Capital Partners Gp LLC which owns 3 million shares in the company valued at $24.02 million. Fidelity Management and Research Company is the second biggest holder with 3 million shares currently valued at 20.62 million whilst Morgenthaler Management Partners IX LLC has 2 million shares valued at 16.56 million.

Total shares held by institutions as of the most recent company filings are 11,089,592 with a reported 996,014 bought and 36,151 sold. These holdings make up 66.64% of the company’s outstanding shares.

Currently insiders hold 183,317 shares in the business which makes up 1.01% of shares. The biggest holder currently is Dr. Susan M. Molineaux, PhD who owns 109,112 shares (0.60% of those outstanding), whilst Dr. Christopher J. Molineaux holds 39,542 (0.22% of shares outstanding) and Mr. William D. Waddill holds 15,625 (0.09% of shares outstanding).

The stock increased 1.88% or $0.12 during the last trading session, hitting $9.98. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 34.37% over the past 6 months and is uptrending.